SynthesisBMC cancer2025
Assessing first-line treatment for advanced EGFR-mutated NSCLC in diverse clinicopathological subgroups: a systematic review and network meta-analysis.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prevalence and Clinical Implications of Somatic and Germline EGFR Mutations in Patients with Non-Small-Cell Lung Cancer.Cancers · 2026Review
- Radiation induces an EGFR-dependent lactate-epigenetic program underlying synergy with EGFR inhibition.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- The Prognostic and Mutational Characteristics of Multiple Early-stage Lung Cancers Manifesting as Subsolid Nodules.Current medical imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis network meta-analysis (NMA) aimed to indicate the most effective first-line therapeutic options for advanced EGFR-mutated NSCLC, particularly considering their specific clinicopathological characteristics.
methodsArticles in the EMBASE, Cochrane Library, PubMed, and Web of Science databases and conference abstracts published as of December 2023, were searched to obtain data from randomized controlled trials (RCTs) of the first-line treatment of advanced EGFR-mutated NSCLC cases with EGFR-TKIs alone or together with other agents.
results37 RCTs including 24 treatment regimens were incorporated into this NMA. With respect to the overall patient cohort, osimertinib + chemotherapy (CT) was associated with the greatest benefit to progression-free survival (PFS), whereas amivantamab + lazertinib yielded the greatest benefit to overall survival (OS). Osimertinib + CT yielded the best PFS outcomes irrespective of patient gender or EGFR mutation subtype. The combinations of amivantamab + lazertinib and icotinib + CT provided the best respective PFS outcomes in Asian and elderly patient cohorts. With respect to OS outcomes, afatinib + cetuximab provided the best outcomes for 19del and male cases, whereas dacomitinib provided the best OS for females and cases with L858R mutations. The respective gefitinib + CT and erlotinib + bevacizumab regimens were also associated with the greatest improvements in the OS of Asian and elderly cases.
conclusionsThis NMA revealed that cases with EGFR-mutated NSCLC may benefit from different first-line treatment regimens according to their clinicopathological characteristics. On the whole, osimertinib plus CT and amivantamab plus lazertinib emerged as the most noticeable treatment modalities for such cases. (PROSPERO ID: CRD42024506995).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.